Liposome Membrane Stability via sPLA2 Hydrolysis and Calcium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liposome formulations face challenges in maintaining stability during storage and transport, leading to uncontrolled drug release due to leakiness of the liposome membrane, which affects their efficacy and safety for targeted drug delivery, particularly in cancer therapy where triggered release at specific sites is desired.
Innovation Solution
Designing liposomes with a specific lipid composition, including anionic lipids (25-45 mol%) and hydrophilic polymers like PEG, combined with zwitterionic phospholipids and ether-phospholipids, to achieve controlled hydrolysis by secretory phospholipase A2 (sPLA2) at tumor sites, while stabilizing the formulation with divalent cations like calcium gluconate to reduce leakage and enhance stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liposomes are prepared with conventional lipid compositions, then they can encapsulate drugs, but they exhibit membrane leakiness leading to uncontrolled drug release during storage and transport
Solution Approach 1:
The patent modifies the lipid composition parameters by incorporating specific ratios of anionic lipids (25-45 mol%), zwitterionic phospholipids, and cholesterol, along with controlling chain length and saturation levels. These parameter changes optimize the membrane's physical-chemical properties to reduce leakiness while maintaining drug encapsulation capability.
Solution Approach 2:
The patent creates a composite lipid structure combining multiple types of lipids (anionic, zwitterionic, saturated, unsaturated) and cholesterol in specific proportions. This composite approach allows the membrane to simultaneously achieve structural integrity, controlled permeability, and stability under physiological conditions.
2Stability of the object's composition
If liposomes are designed for stable membrane structure, then they maintain integrity during storage, but they may not release drugs effectively at target sites
Solution Approach 1:
The patent designs a dynamic membrane system that adapts its properties in response to environmental cues. The lipid composition allows the membrane to maintain stability under storage conditions but becomes more permeable or undergoes structural changes at the target site, enabling controlled drug release when needed.
Solution Approach 2:
The patent creates regions within the liposome membrane with different lipid compositions and properties. Specific lipid domains or regions are designed to respond to local conditions at the target site, allowing selective drug release at the desired location while maintaining overall membrane stability during circulation.
3Quantity of substance
If liposomes use high anionic lipid content to enhance drug encapsulation, then they improve drug loading, but they become more susceptible to phospholipase A2 hydrolysis
Solution Approach 1:
The patent optimizes the anionic lipid content within a specific range (25-45 mol%) rather than using maximum levels. This parameter optimization balances the competing requirements of sufficient drug encapsulation capacity with reduced susceptibility to enzymatic hydrolysis, achieving both goals simultaneously.
Solution Approach 2:
The patent introduces protective mechanisms such as surface-modifying lipids or coating materials that act as intermediaries between the anionic lipid core and phospholipase A2 enzymes. These intermediaries reduce enzyme access or activity while preserving the beneficial drug encapsulation properties of the anionic lipids.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in improved stability and controlled release of bioactive agents, reducing uncontrolled leakage and enhancing the therapeutic efficacy of liposomes by ensuring targeted delivery and prolonged circulation in the bloodstream, thereby improving the treatment of cancer and inflammatory diseases.
Implementation Method 1
phospholipase A 2 (PLA 2) will hydrolyse lipids of the liposome
Implementation Method 2
stabilizing the formulation with divalent cations like calcium gluconate to reduce leakage and enhance stability
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.